3//SEC Filing
New Leaf BPO Management II, L.L.C 3
Accession 0001209191-19-008266
CIK 0001708493other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 7:02 PM ET
Size
18.7 KB
Accession
0001209191-19-008266
Insider Transaction Report
Form 3
New Leaf BPO Management II, L.L.C
10% Owner
Holdings
- (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (464,281 underlying) - (indirect: See footnote)
Series B Convertible Preferred Stock
Exercise: $0.00→ Common Stock (1,564,272 underlying) - (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (464,281 underlying)
New Leaf Ventures III, L.P.
10% Owner
Holdings
- (indirect: See footnote)
Series B Convertible Preferred Stock
Exercise: $0.00→ Common Stock (1,564,272 underlying) - (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (464,281 underlying) - (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (464,281 underlying)
Holdings
- (indirect: See footnote)
Series B Convertible Preferred Stock
Exercise: $0.00→ Common Stock (1,564,272 underlying) - (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (464,281 underlying) - (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (464,281 underlying)
Holdings
- (indirect: See footnote)
Series B Convertible Preferred Stock
Exercise: $0.00→ Common Stock (1,564,272 underlying) - (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (464,281 underlying) - (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (464,281 underlying)
Holdings
- (indirect: See footnote)
Series B Convertible Preferred Stock
Exercise: $0.00→ Common Stock (1,564,272 underlying) - (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (464,281 underlying) - (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (464,281 underlying)
New Leaf BPO Associates II, L.P.
10% Owner
Holdings
- (indirect: See footnote)
Series B Convertible Preferred Stock
Exercise: $0.00→ Common Stock (1,564,272 underlying) - (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (464,281 underlying) - (indirect: See footnote)
Series C Convertible Preferred Stock
Exercise: $0.00→ Common Stock (464,281 underlying)
Footnotes (5)
- [F1]All series of convertible preferred stock will automatically convert into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
- [F2]These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein.
- [F3]Each of Ronald M. Hunt, a member of the Issuer's board of directors, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-III (the "NLV-III Managers"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F4]These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. ("BPO-II"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. ("NLBA-II"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. ("BPO Management-II"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein.
- [F5]Each of Ronald M. Hunt, Vijay K. Lathi, Liam T. Ratcliffe and Isaac A. Manke, the managers of BPO Management-II (the "BPO-II Managers"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Documents
Issuer
Harpoon Therapeutics, Inc.
CIK 0001708493
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001740755
Filing Metadata
- Form type
- 3
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 7:02 PM ET
- Size
- 18.7 KB